The Red Section | Published:

Managing Clostridium difficile: an old bug with new tricks

The American Journal of Gastroenterologyvolume 113pages932935 (2018) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98.

  2. 2.

    Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792–801.

  3. 3.

    Crobach MJ, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63–81.

  4. 4.

    Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in Inflammatory Bowel Disease: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017;15:166–74.

  5. 5.

    Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423–7. discussion 427-9

  6. 6.

    Fischer M, Sipe B, Cheng YW, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8:289–302.

  7. 7.

    Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–6.

  8. 8.

    McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–75.

  9. 9.

    Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:2402–9.

  10. 10.

    Khoruts A, Rank KM, Newman KM, et al. Inflammatory Bowel Disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14:1433–8.

  11. 11.

    Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149:223–37.

  12. 12.

    Allegretti JR, Kassam Z, Osman M, et al. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc. 2018;87:18–29.

  13. 13.

    Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142–9.

  14. 14.

    Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985–93.

  15. 15.

    Carignan A, Poulin S, Martin P, et al. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol. 2016;111:1834–40.

  16. 16.

    Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile Infection. N Engl J Med. 2017;376:305–17.

Download references

Author information

Affiliations

  1. Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA

    • Stephen M. Vindigni MD, MPH
    •  & Christina M. Surawicz MD
  2. Alaska Native Tribal Health Consortium, Alaska Native Medical Center, Anchorage, Alaska, USA

    • Stephen M. Vindigni MD, MPH

Authors

  1. Search for Stephen M. Vindigni MD, MPH in:

  2. Search for Christina M. Surawicz MD in:

Guarantor of the article

Christina Surawicz.

Specific author contributions

S.M.V. and C.M.S. wrote text sections and edited them together.

Financial support

None.

Potential competing interests

None.

Corresponding author

Correspondence to Stephen M. Vindigni MD, MPH.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41395-018-0059-y